



www.elsevier.nl/locate/ejphar

# Functional assessment of recombinant human $\alpha_2$ -adrenoceptor subtypes with Cytosensor microphysiometry

Marjo Pihlavisto \*, Mika Scheinin

Department of Pharmacology and Clinical Pharmacology, University of Turku, MediCity, Tykistökatu 6 A, FIN-20520, Turku, Finland Received 24 June 1999; received in revised form 23 September 1999; accepted 12 October 1999

#### Abstract

We applied the Cytosensor Microphysiometry system to study the three human  $\alpha_2$ -adrenoceptor subtypes,  $\alpha_{2A}$ ,  $\alpha_{2B}$  and  $\alpha_{2C}$ , expressed in Chinese hamster ovary (CHO) cells, and assessed its potential in the quantitative monitoring of agonist activity. The natural full agonist, (-)-noradrenaline, was used to define agonist efficacy. The imidazole derivative dexmedetomidine was a potent full agonist of all three receptor subtypes. The imidazolines clonidine and UK 14,304 (5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine) appeared to be partial agonists at  $\alpha_{2B}$ -adrenoceptors ( $E_{max} \approx 60\%$  of (-)-noradrenaline) but full agonists at  $\alpha_{2A}$ - and  $\alpha_{2C}$ -adrenoceptors. The responses mediated by all three  $\alpha_2$ -adrenoceptor subtypes were partly inhibited by the sodium-hydrogen (Na $^+$ /H $^+$ ) exchange inhibitor, MIA (5-(N-methyl-N-isobutyl)-amiloride). The agonist responses were totally abolished by pretreatment with pertussis toxin in cells with  $\alpha_{2A}$ - and  $\alpha_{2C}$ -adrenoceptors, and partly abolished in cells with  $\alpha_{2B}$ -adrenoceptors. The residual signal in  $\alpha_{2B}$ -cells was sensitive to the intracellular Ca<sup>2+</sup> chelator, BAPTA (1,2-bis(2-aminophenoxy)ethane-N, N, N, N-tetraacetic acid acetoxymethyl ester). Cholera toxin (which acts on  $G_s$ -proteins) had no effect on the agonist responses. The results suggest that the extracellular acidification responses mediated by all three human  $\alpha_2$ -adrenoceptor subtypes are dependent on Na $^+$ /H $^+$ exchange and  $G_{i/o}$  pathways, and that  $\alpha_{2B}$ -adrenoceptors are capable of coupling to another,  $G_{i/o}$ -independent and Ca $^{2+}$ -dependent signaling pathway. © 1999 Elsevier Science B.V. All rights reserved.

Keywords: α<sub>2</sub>-Adrenoceptor; Functional activity; Microphysiometry; CHO (Chinese hamster ovary) cell; G-protein; Signal transduction

## 1. Introduction

The  $\alpha_2$ -adrenoceptors ( $\alpha_{2A}$ ,  $\alpha_{2B}$  and  $\alpha_{2C}$ ) are members of a large family of cell membrane receptors which mediate their signals through heterotrimeric guanine nucleotide binding regulatory proteins (G-proteins). The  $\alpha_2$ -adrenoceptors have been demonstrated to be capable of mediating signals to several different cellular effectors, including adenylyl cyclases, ion channels (K<sup>+</sup> and Ca<sup>2+</sup>) and phospholipases (A<sub>2</sub>, C and D) (Limbird, 1988; Cotecchia et al., 1990; Duzic and Lanier, 1992; MacNulty et al., 1992). In most cases,  $\alpha_2$ -adrenergic regulation of these pathways is sensitive to pertussis toxin, suggesting that GTP-binding proteins in the  $G_i/G_o$  subfamily mediate these effects (Kurose et al., 1991; Limbird et al., 1995). An exception to this pertussis toxin-sensitivity is activation

E-mail address: mpihla@utu.fi (M. Pihlavisto)

of adenylyl cyclase, which appears to be mediated by  $G_s$  (Pohjanoksa et al., 1997). On the other hand, pertussis toxin-sensitive G-proteins,  $G_{i\alpha 2}$  and  $G_{i\alpha 3}$ , have been shown to mediate 5-HT<sub>1A</sub>-receptor activation of Na<sup>+</sup>/H<sup>+</sup>exchange in transfected Chinese hamster ovary (CHO) cells (Garnovskaya et al., 1997). Also other forms of heterotrimeric GTP-binding proteins,  $G_{\alpha q}$ ,  $G_{\alpha 12}$  and  $G_{\alpha 13}$ , have been shown to activate Na<sup>+</sup>/H<sup>+</sup>exchange in mammalian cells through protein kinase C-dependent and -independent signaling pathways (Dhanasekaran et al., 1994; Lin et al., 1996; Orlowski and Grinstein, 1997). The coupling of  $\alpha_2$ -adrenoceptor subtypes to regulation of Na<sup>+</sup>/H<sup>+</sup>exchange has not been investigated in a standardized test model such as transfected CHO cells.

Continuous monitoring of extracellular pH with the Cytosensor Microphysiometry system allows the detection and quantitation of functional responses from living cells (McConnell et al., 1992). The microphysiometry assay continuously monitors the extracellular pH surrounding cells in culture, and reports receptor activation by measuring increases in extracellular acidification rate, occurring

 $<sup>^{\</sup>ast}$  Corresponding author. Tel.: +358-2-333-7021; telefax: +358-2-333-7000.

in response to agonist stimulation. Several receptor types have been shown to produce responses upon agonist activation allowing quantitative pharmacological analysis, including the use of modulators and antagonists (Chio et al., 1993; Castro et al., 1996; Brown et al., 1997; Garnovskaya et al., 1997; Smith et al., 1998; Wood et al., 1999).

We have now performed the first application of this method to study the three human  $\alpha_2$ -adrenoceptor subtypes  $\alpha_{2A}$ ,  $\alpha_{2B}$  and  $\alpha_{2C}$ , heterologously expressed in stably transfected CHO cell lines. The natural full agonist, (-)-noradrenaline, was used to determine maximal responsivity. The experiments were performed using four different agonists, (-)-noradrenaline, clonidine, dexmedetomidine and 5-bromo-N-(4,5-dihydro-1 H-imidazol-2-yl)-6-quinoxalinamine (UK 14,304). We were interested in identifying the precise signal transduction pathways utilized by  $\alpha_2$ -adrenoceptor subtypes in recombinant CHO cells. Experiments involving pharmacological perturbations of the signal transduction pathways of CHO cells were therefore performed. Our results support the usefulness of this new assay for agonist characterization and for studies on coupling and signaling mechanisms of  $\alpha_2$ adrenoceptors.

#### 2. Materials and methods

#### 2.1. Materials

[<sup>3</sup>H]RX821002 (2-(2-methoxy-1,4-benzodioxan-2-yl)-2-imidazoline) was from Amersham (Buckinghamshire, UK; specific activity 52 Ci/mmol). BAPTA (1,2-bis(2-aminophenoxy)ethane-*N*, *N*, *N*, *N*-tetraacetic acid acetoxymethyl ester), MIA (5-(*N*-methyl-*N*-isobutyl)-amiloride) and UK 14,304 were from Research Biochemicals (Natick, MA, USA). Dexmedetomidine was a gift from Orion-Farmos (Turku, Finland). The following compounds were obtained from Sigma (St. Louis, MO, USA): (—)-noradrenaline (bitartrate salt), clonidine, Geneticin<sup>®</sup> (G418), pertussis toxin and cholera toxin. Cell culture reagents were supplied by Gibco (Gaithersburg, MD, USA). Other chemicals were of analytical or reagent grade, and were purchased from commercial suppliers.

#### 2.2. Transfection and cell culture

Adherent CHO cells (American Type Culture Collection, Rockville, MD, USA) were cultured in  $\alpha$  MEM ( $\alpha$ -minimum essential medium) supplemented with 2 mM glutamine, 26 mM NaHCO<sub>3</sub>, 5% heat-inactivated fetal bovine serum, 50 U/ml penicillin and 50  $\mu$ g/ml streptomycin. The cells were grown in 5% CO<sub>2</sub> at 37°C. Cells were harvested into chilled phosphate-buffered saline, pelleted and suspended in  $\alpha$  MEM for Cytosensor Microphys-

iometry. The pMAMneo-based (Clontech Laboratories, Palo Alto, CA, USA) expression constructs were transfected into CHO cells with the Lipofectin® reagent kit (Gibco, Paisley, UK). For each transfection 3  $\mu$ g plasmid DNA was used per  $5 \times 10^4$  cells. Neomycin (G418) resistant clones (750  $\mu$ g/ml) were selected and examined for their ability to bind the  $\alpha_2$ -adrenoceptor antagonist [ $^3$ H]RX821002. The transfected cells chosen for further experiments were subsequently maintained in 250  $\mu$ g/ml G418 (Pohjanoksa et al., 1997).

## 2.3. Radioligand binding

The receptor densities  $(B_{\text{max}})$  and the corresponding radioligand  $K_d$  values for the cell clones were determined in saturation binding experiments using [3H]RX821002 as radioligand (Halme et al., 1995). No specific binding of [3H]RX821002 was observed in non-transfected CHO cells. Two expression levels of each receptor, approximately 0.3-0.7 pmol/mg total cellular protein ("low") and 1.3-3.0 pmol/mg ("high"), were chosen for functional studies. They were:  $B_{\rm max}$  1.3  $\pm$  0.2 pmol/mg,  $K_{\rm d}$  0.89  $\pm$  0.27 nM (high) and  $B_{\rm max}$  0.3  $\pm$  0.02 pmol/mg,  $K_{\rm d}$  0.48  $\pm$  0.08 nM (low) for  $\alpha_{2A}$ -adrenoceptors,  $B_{\text{max}}$  2.6  $\pm$  0.5 pmol/mg,  $K_{\rm d}$  4.37  $\pm$  0.55 nM (high) and  $B_{\rm max}$  0.54  $\pm$ 0.18 pmol/mg,  $K_{\rm d}$  2.20  $\pm$  0.08 nM (low) for  $\alpha_{\rm 2B}$ -adrenoceptors and  $B_{\rm max}$  3.0  $\pm$  0.4 pmol/mg,  $K_{\rm d}$  1.28  $\pm$  0.12 nM (high) and  $B_{\rm max}$  0.65  $\pm$  0.12 pmol/mg,  $K_{\rm d}$  0.98  $\pm$ 0.13 nM (low) for  $\alpha_{2C}$ -adrenoceptors (Pohjanoksa et al., 1997; Peltonen et al., 1998).




Fig. 1. Acidification rate data taken from Cytosoft, the Cytosensor software. CHO cells expressing the  $\alpha_{2B}$ -adrenoceptor subtype (2.6 pmol/mg protein) were exposed to increasing concentrations of ( – )-noradrenaline, clonidine and ( – )-noradrenaline with 100  $\mu M$  rauwolscine. Non-transfected CHO cells were similarly exposed to increasing concentrations of ( – )-noradrenaline (control). Cells were exposed to successive 50 s applications of agonist, at the concentrations indicated, and a 30 min wash was employed between successive agonist exposures. Increases in acidification rate due to agonist exposure are expressed as % increase over normalized baseline. Data are representative of three to six separate experiments. Each division of the abscissa represents 50 s agonist application and 30 min wash.

#### 2.4. Measurement of extracellular acidification rate

Extracellular acidification rates were measured using a four-channel Cytosensor Microphysiometry instrument (Molecular Devices., Menlo Park, CA, USA). Cultured CHO cells were seeded into 12-mm capsule cups at  $3\times10^5$  cells/cup and incubated in 5% CO $_2$  at  $37^{\circ}\text{C}$  for 20 h. The capsule cups were loaded into the sensor chambers of the instrument and the chambers were perfused with running medium (bicarbonate-free  $\alpha$  MEM supplemented with 2 mM glutamine, 26 mM NaCl, 50 U/ml penicillin and 50  $\mu\text{g/ml}$  streptomycin), at a flow rate of 100  $\mu\text{l/min}$ . Agonists were diluted into running medium and perfused through a second fluid path. Valves directed the flow from either fluid path to the sensor chamber. During each 2 min pump cycle, the pump was on for 1 min 20 s and was then

switched off for the remaining 40 s. The pH of the running medium was recorded from 1:25 to 1:55 min. The pump was started at 2 min to start the next cycle. Cells were exposed to agonists for 50 s. A 15 to 30 min wash period was employed between successive agonist exposures. This stimulation protocol was validated in preliminary experiments. The rate of acidification of the chamber was calculated by the Cytosoft program (Molecular Devices). All four chambers of the instrument had identical values for the response in mV s<sup>-1</sup>/change in pH units, i.e., 61 mV s<sup>-1</sup>/pH unit. Changes in the rate of acidification were calculated as the difference between the maximum effect after agonist addition and the average of three measurements taken immediately before agonist addition.

In some experiments, confluent cells were preincubated with pertussis toxin (200 ng/ml) (Garnovskaya et al.,




Fig. 2. Concentration–response curves generated from the extracellular acidification rate data. The responses relative to 100  $\mu$ M (–)-noradrenaline (NA) were calculated for  $\alpha_{2A}$ ,  $\alpha_{2B}$  and  $\alpha_{2C}$  adrenoceptor subtypes with "high" (1.3–3.0 pmol/mg protein) receptor densities. Values are means  $\pm$  S.E. from three to six separate experiments.

1997; Peltonen et al., 1998) or cholera toxin (1  $\mu$ g/ml) (Shimegi et al., 1994) for 18–20 h before the capsule cups were loaded into the sensor chambers. Other test substances, such as the Na<sup>+</sup>/H<sup>+</sup>exchange inhibitor, MIA and the intracellular Ca<sup>2+</sup>chelator, BAPTA, were added 15 min (MIA, 10  $\mu$ M) (Garnovskaya et al., 1997) or 30 min (BAPTA, 50  $\mu$ M) (Jansson et al., 1991) before agonists. Baseline acidification rates were normalised to 100% and changes due to agonist exposure were calculated as percent increases over normalized baseline. Control responses were recorded in the presence of a maximally effective concentration of (-)-noradrenaline (100  $\mu$ M) at the start and end of each agonist concentration–effect experiment. No desensitization was observed.

#### 2.5. Calculations

 $EC_{50}$  and maximal response ( $E_{max}$ ) values were calculated using the curve-fitting programme GraphPad PRISM (GraphPad Software, San Diego, CA, USA). The results are expressed as means  $\pm$  S.E. of three to six separate experiments. Student's t-test with two-tailed probabilities, or one-way analysis of variance (ANOVA) together with the Student-Newman-Keuls-test were used to test the statistical significance of the observed differences between group means.

#### 3. Results

#### 3.1. Agonist activities

Functional activation of  $\alpha_2$ -adrenoceptors in intact CHO cells was assessed with Cytosensor Microphysiometry using four different agonists, (-)-noradrenaline, clonidine, dexmedetomidine and UK 14,304. The natural full agonist, (-)-noradrenaline (100 μM), was used as a reference compound to determine maximal responsivity. The response to (-)-noradrenaline was blocked by the  $\alpha_2$ -adrenoceptor antagonist, rauwolscine (100 µM), and was absent in non-transfected CHO cells (Fig. 1). The imidazole derivative dexmedetomidine was a potent full agonist of all three receptor subtypes; its efficacy actually exceeded that of (-)-noradrenaline in some cases (P < 0.001 for  $\alpha_{2A}$ ), as shown in Fig. 2 and Table 1. The imidazolines clonidine and UK 14,304 appeared to be partial agonists at  $\alpha_{2B}$ -adrenoceptors ( $E_{\text{max}} \approx 60\% \text{ of } (-)$ -noradrenaline; P< 0.005) (Fig. 2.) but full agonists at  $\alpha_{2A}$ - and  $\alpha_{2C}$ -adrenoceptors. Also the efficacy of UK 14,304 exceeded that of (-)-noradrenaline at  $\alpha_{2A}$ -adrenoceptors (P < 0.01). The rank order of agonist potency was dexmedetomidine > UK 14,304 > clonidine > (-)-noradrenaline for  $\alpha_{2A}$ - and  $\alpha_{2C}$ -adrenoceptor subtypes, and dexmedetomidine > UK  $14,304 \ge (-)$ -noradrenaline > clonidine for the  $\alpha_{2B}$ adrenoceptor subtype.

Table 1

Comparison of half-maximal effective concentrations (EC $_{50}$ ) and maximal effects ( $E_{\rm max}$ ) of agonists at "high" (1.3–3.0 pmol/mg) expression levels of each receptor subtype ( $\alpha_{\rm 2A}$ ,  $\alpha_{\rm 2B}$  and  $\alpha_{\rm 2C}$ ), in transfected CHO cell lines in the Cytosensor Microphysiometry assay. Values are means  $\pm$  S.E. from three to six separate experiments

The EC $_{50}$  values were estimated from log concentration–response curves by non-linear regression analysis, and  $E_{\rm max}$  values are relative to a maximally effective concentration of (–)-noradrenaline (NA, 100  $\mu$ M).

Agonist	$K_i$ (nM) <sup>a</sup>	EC <sub>50</sub> (nM)	$E_{\rm max}$ (% of NA)
CHO- α <sub>2 A</sub>			
( – )-Noradrenaline	$277 \pm 145$	$756 \pm 107$	$100 \pm 2$
Clonidine	$17.2 \pm 1.54$	$283 \pm 142$	$105 \pm 11$
Dexmedetomidine	$2.20 \pm 0.25$	$67.1 \pm 5$	$132 \pm 7^{b}$
UK 14,304	$12.9 \pm 1.77$	$159 \pm 49$	$125\pm10^{\rm c}$
CHO- α <sub>2 B</sub>			
( – )-Noradrenaline	$500 \pm 206$	$200 \pm 57$	$100 \pm 9$
Clonidine	$56.0 \pm 12.6$	$578 \pm 190$	$73 \pm 8^{d}$
Dexmedetomidine	$3.33 \pm 1.41$	$0.29 \pm 0.01$	$107 \pm 8$
UK 14,304	$525 \pm 38$	$178\pm11$	$66 \pm 11^{d}$
CHO- α <sub>2C</sub>			
( – )-Noradrenaline	$256 \pm 102$	$369 \pm 101$	$100 \pm 6$
Clonidine	$96.9 \pm 8.69$	$199 \pm 154$	95 ± 9
Dexmedetomidine	$2.97 \pm 1.78$	$0.50 \pm 0.17$	$115 \pm 9$
UK 14,304	$361 \pm 101$	$78.2 \pm 39$	$98 \pm 10$

<sup>&</sup>lt;sup>a</sup>K<sub>i</sub>-values published by Pohjanoksa et al. (1997), except for UK 14,304, which was determined in the current study.

The relative maximal effect ( $E_{\rm max}$ ) of these compounds (compared to (-)-noradrenaline) and their potency (EC  $_{50}$ ) values were similar in CHO cells with "low" and "high" (0.3–0.7 or 1.3–3.0 pmol/mg total cellular protein) expression levels of  $\alpha_2$ -adrenoceptor subtypes (data not shown). In absolute terms, the increases in extracellular acidification rates ( $\mu$ V s $^{-1}$ ) induced by (-)-noradrenaline were different for these two receptor densities, "low" and "high". Thus, in  $\alpha_{2A}$  maximal extracellular acidification rate increases were 30–40  $\mu$ V s $^{-1}$  ("low") and 70–90  $\mu$ V s $^{-1}$  ("high"), in  $\alpha_{2E}$  40–50  $\mu$ V s $^{-1}$  ("low") and 80–100  $\mu$ V s $^{-1}$  ("high"), and in  $\alpha_{2C}$  40–50  $\mu$ V s $^{-1}$  ("low") and 90–110  $\mu$ V s $^{-1}$  ("high").

## 3.2. Signal transduction pathways

Intact cells were pretreated with the inhibitors, MIA, pertussis toxin and cholera toxin, and with the intracellular  $\text{Ca}^{2+}$  chelator, BAPTA, and with their different combinations, to assess the roles of some possible signal transduction pathways in the receptor responses in the Cytosensor Microphysiometry system. Changes in acidification rates were induced with 1  $\mu\text{M}$  dexmedetomidine in pretreated and control cell chambers.

The responses mediated by  $\alpha_{2A}$ - and  $\alpha_{2C}$ -adrenoceptors were totally abolished by pretreatment of intact CHO cells

 $<sup>^{\</sup>rm b}P < 0.001$  compared to ( – )-noradrenaline.

 $<sup>^{</sup>c}P < 0.01$  compared to (-)-noradrenaline.

 $<sup>^{\</sup>rm d}P < 0.005$  compared to (-)-noradrenaline.

with pertussis toxin (P < 0.001), and were partly abolished also in cells with  $\alpha_{2B}$ -adrenoceptors (72%) (P < 0.001). This indicated that the observed acidification rate increases were either entirely or partly  $(\alpha_{2B})$  due to the coupling of α<sub>2</sub>-adrenoceptors to pertussis toxin-sensitive G-proteins  $(G_i/G_o)$ . The residual signal in  $\alpha_{2B}$ -cells was sensitive to the intracellular Ca<sup>2+</sup> chelator, BAPTA (50 μM). BAPTA alone inhibited  $\alpha_2$ -adrenoceptor-mediated acidification responses to 1  $\mu$ M dexmedetomidine by 65% in  $\alpha_{2A}$ -(P < 0.005), by 71% in  $\alpha_{2B}$ - (P < 0.001) and by 70% in  $\alpha_{2C}$ -expressing cells (P < 0.005). The responses to 1  $\mu$ M dexmedetomidine mediated by all three  $\alpha_2$ -adrenoceptor subtypes were partly inhibited by the Na<sup>+</sup>/H<sup>+</sup>exchange inhibitor, MIA (10 µM). The maximal inhibitory effect with 10  $\mu$ M MIA was 71% for  $\alpha_{2A}$  (P < 0.005), 62% for  $\alpha_{2B}$  (P < 0.005) and 51% for  $\alpha_{2C}$  (P < 0.005) (Fig. 3). In addition, the inhibitory effects of BAPTA and MIA added simultaneously were 63%–77% for all three subtypes.




Fig. 3. The functional responses mediated by all three  $\alpha_2$ -adrenoceptor subtypes (1.3–3.0 pmol/mg protein) were fully, partly or not at all inhibited by pertussis toxin (200 ng/ml), cholera toxin (1  $\mu$ g/ml), MIA (10  $\mu$ M) or BAPTA (50  $\mu$ M). Changes in acidification rates were induced with 1  $\mu$ M dexmedetomidine in pretreated and control cell chambers. Values are means  $\pm$  S.E. from three to five separate experiments. \*\*\*\*P < 0.001; \*\*P < 0.005; \*P < 0.01 compared to control; °P < 0.005 vs. BAPTA and P < 0.005 vs pertussis toxin.

Cholera toxin (which acts on  $G_s$ -proteins) had no statistically significant effect on extracellular acidification responses to 1  $\mu M$  dexmedetomidine, indicating no mediation of the effect through  $G_s$ -proteins.

#### 4. Discussion

This study demonstrated that transfected human  $\alpha_2$ -adrenoceptor subtypes are coupled to regulation of proton extrusion rate (extracellular acidification) in intact CHO cells. Microphysiometry (McConnell et al., 1992) proved to be useful in the analysis of functional coupling of agonist stimulation at the three  $\alpha_2$ -adrenoceptor subtypes.

Guanine nucleotide effects on agonist binding are a characteristic of G-protein-linked  $\alpha_2$ -adrenoceptors (Jansson et al., 1994; Halme et al., 1995). At the second messenger level, adenylyl cyclase inhibition has been classically described as a response to activation of  $\alpha_2$ -adrenoceptor subtypes (Pohjanoksa et al., 1997). Since neither binding assays nor adenylyl cyclase responses alone give sufficient information about agonist–receptor interactions, the specific functional characteristics of each  $\alpha_2$ -adrenoceptor subtype have been further elucidated in different assays monitoring G-protein activation (Virolainen et al., 1997; Peltonen et al., 1998) and intracellular Ca<sup>2+</sup> responses (Kukkonen et al., 1997; Soini et al., 1998), and now with the Cytosensor Microphysiometry assay system.

In the current study, clear differences in efficacy at the  $\alpha_{2B}$ -adrenoceptor subtype could be observed between the full agonists (–)-noradrenaline and dexmedetomidine and the partial agonist clonidine. Also UK 14,304 appeared to be a partial agonist at  $\alpha_{2B}$ -adrenoceptors. The result for UK 14,304 at  $\alpha_{2B}$ -adrenoceptors was unexpected, because it has been a full agonist in adenylyl cyclase assays (Jansson et al., 1994; Pohjanoksa et al., 1997). However, in line with the present results, it was recently shown with a [35S]GTPγS binding assay and CHO cell membranes that UK 14,304 acts as full agonist at the  $\alpha_{2A}$ -adrenoceptor subtype but as a partial agonist at  $\alpha_{2B}$ - and  $\alpha_{2C}$ -adrenoceptors (Peltonen et al., 1998). The rank orders of potency determined for the tested \(\alpha\_2\)-adrenoceptor agonists in stimulating increases in extracellular acidification rate in CHO cells were in general agreement with those determined in studies on the inhibition of forskolin-stimulated adenylyl cyclase activity (Pohjanoksa et al., 1997), and GTP<sub>γ</sub>S-binding assays (Jasper et al., 1998; Peltonen et al., 1998). GTP<sub>y</sub>S-binding assays give direct information on receptor-mediated G-protein activation, in contrast to the currently employed Microphysiometry technique, which measures the production of acidic metabolites by complex living cell systems.

The potency and relative efficacy (compared to (-)-noradrenaline) of agonists were not dependent on receptor density in Cytosensor Microphysiometry assays. A high

receptor density (1.3-3.0 pmol/mg) did not interfere with discrimination between full and partial agonists compared to cells with a lower receptor density (0.3-0.7 pmol/mg), as has previously been the case in adenylyl cyclase assays (Pohjanoksa et al., 1997). At  $\alpha_{2A}$ -adrenoceptors, dexmedetomidine and UK 14,304 were capable of inducing greater maximal responses than the endogenous ligand (–)-noradrenaline. One possible explanation for this is that the intensity of the response may be related to the relative affinities of the agonist for the various active receptor conformations. Alternatively, the different responses may be related to the kinetics of the drug-receptor interactions.

Our results indicate that the  $\alpha_{2B}$ -adrenoceptor subtype clearly differs from the other two  $\alpha_2$ -adrenoceptor subtypes in its coupling to second messenger systems. We conclude that all three  $\alpha_2$ -adrenoceptor subtypes caused receptor-mediated, concentration-dependent increases in extracellular acidification rate, which were dependent on pertussis toxin-sensitive G-proteins ( $G_i$ ), availability of intracellular  $Ca^{2+}$  and a  $Na^+/H^+$  exchange mechanism, but did not involve the action of  $G_s$ -proteins. In addition, no marked differences in the proportional involvement of these signaling pathways could be seen between the receptor subtypes, with the exception of the  $\alpha_{2B}$ -adrenoceptor subtype, which was markedly pertussis toxin-insensitive compared to the other two subtypes.

In contrast to assays measuring changes in second messenger concentrations, the current Microphysiometry assay gives direct information on receptor-mediated functional activation in complex living cell systems. Because the system permits rapid bioassays from living, intact cells, it appears to offer significant advantages for possible applications in basic research and in biotechnology (McConnell et al., 1992). Our results support the usefulness of this new assay for agonist characterization and for screening of new  $\alpha_2$ -adrenoceptor ligands.

## Acknowledgements

This study was financially supported by grants from the Technology Development Centre of Finland, the Academy of Finland, and the European Commission (BMH4-CT98-3373). The authors wish to thank K. Pohjanoksa and A. Marjamäki for providing the recombinant CHO cells. The authors are also grateful to Anna-Mari Pekuri and Ulla Uoti for skillful technical assistance.

### References

Brown, M.J., Wood, M.D., Coldwell, M.C., Bristow, D.R., 1997. Measurement of GABA<sub>A</sub> receptor function in rat cultured cerebellar granule cells by the Cytosensor microphysiometer. Br. J. Pharmacol. 121, 71–76.

- Castro, S.W., Buell, G., Feniuk, W., Humphrey, P.P.A., 1996. Differences in the operational characteristics of the human recombinant somatostatin receptor types, sst<sub>1</sub> and sst<sub>2</sub>, in mouse fibroblast (Ltk<sup>-</sup>) cells. Br. J. Pharmacol. 117, 639–646.
- Chio, C., Lajiness, M.E., Huff, R.M., 1993. Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol. Pharmacol. 45, 51–60.
- Cotecchia, S., Kobilka, B.K., Daniel, K.W., Nolan, R.D., Lapetina, E.Y., Caron, M.G., Lefkowitz, R.J., Regan, J.W., 1990. Multiple second messenger pathways of α-adrenergic receptor subtypes expressed in eukaryotic cells. J. Biol. Chem. 265, 63–69.
- Dhanasekaran, N., Vara Prasad, M.V.V.S., Wadsworth, S.J., Dermott, J.M., Van Rossum, G., 1994. Protein kinase C-dependent and -independent activation of Na $^+/H^+$  exchanger by  $G\alpha_{12}$  class of G proteins. J. Biol. Chem. 269, 11802–11806.
- Duzic, E., Lanier, S.M., 1992. Factors determining the specificity of signal transduction by guanine nucleotide-binding protein-coupled receptors. J. Biol. Chem. 267, 24045–24052.
- Garnovskaya, M.N., Gettys, T.W., Van Biesen, T., Prpic, V., Chuprun, J.K., Raymond, J.R., 1997. 5-HT<sub>1A</sub> Receptor activates Na $^+$ /H $^+$  exhange in CHO-K1 cells through  $G_{i\alpha\,2}$  and  $G_{i\alpha\,3}$ . J. Biol. Chem. 272, 7770–7776.
- Halme, M., Sjöholm, B., Scheinin, M., 1995. Recombinant human α<sub>2</sub>-adrenoceptor subtypes: comparison of [<sup>3</sup>H]rauwolscine, [<sup>3</sup>H]atipamezole and [<sup>3</sup>H]RX821002 as radioligands. Biochim. Biophys. Acta 1266, 207–214.
- Jansson, C.C., Kukkonen, J., Åkerman, K.E.O., 1991. Muscarinic receptor-linked elevation of cAMP in SH-SY5Y neuroblastoma cells is mediated by Ca<sup>2+</sup> and protein kinase C. Biochim. Biophys. Acta 1095, 255–260.
- Jansson, C.C., Marjamäki, A., Luomala, K., Savola, J.-M., Scheinin, M., Åkerman, K.E.O., 1994. Coupling of human  $\alpha_2$ -adrenoceptor subtypes to regulation of CAMP production in transfected S115 cells. Eur. J. Pharmacol. 266, 165–174.
- Jasper, J.R., Lasnick, J.D., Chang, L.K., Yamanishi, S.S., Chang, T.K., Hsu, S.A.O., Daunt, D.A., Bonhaus, D.W., Eglen, R.M., 1998. Ligand efficacy and potency at recombinant  $\alpha_2$  adrenergic receptors; agonist-mediated [ $^{35}$ S]GTPγS binding. Biochem. Pharmacol. 55, 1035–1043.
- Kukkonen, J.P., Huifang, G., Jansson, C., Wurster, S., Cockcroft, V., Savola, J.-M., Åkerman, K.E.O., 1997. Different apparent modes of inhibition of  $\alpha_{2A}$ -adrenoceptor by  $\alpha_{2}$ -adrenoceptor antagonists. Eur. J. Pharmacol. 335, 99–105.
- Kurose, H., Regan, J.W., Caron, M.G., Lefkowitz, R.J., 1991. Functional interactions of recombinant  $\alpha_2$  adrenergic receptor subtypes and G proteins in reconstituted phospholipid vesicles. Biochemistry 30, 3335–3341.
- Limbird, L.E., 1988. Receptors linked to inhibition of adenylate cyclase: additional signaling mechanisms. FASEB J. 2, 2686–2695.
- Limbird, L.E., MacMillan, L.B., Keefer, J.R., 1995. Specificity in  $\alpha_2$ -adrenoceptor signal transduction: receptor subtypes, coupling to distinct signal transduction pathways and localization to discrete subdomains in target cells. Pharmacol. Commun. 6, 139–145.
- Lin, X., Voyno-Yasenetskaya, T.A., Hooley, R., Lin, C.-Y., Orlowski, J., Barber, D.L., 1996.  $G\alpha 12$  Differentially regulates  $Na^+-H^+$  exchanger isoforms. J. Biol. Chem. 271, 22604–22610.
- MacNulty, E.E., McClue, S.J., Carr, I.C., Jess, T., Wakelam, M.J.O., Milligan, G., 1992. The α<sub>2</sub>-C10 adrenergic receptors expressed in rat 1 fibroblasts can regulate both adenylyl cyclase and phospholipase D-mediated hydrolysis of phosphatidylcholine by interacting with pertussis toxin-sensitive guanine nucleotide-binding proteins. J. Biol. Chem. 267, 2149–2156.
- McConnell, H.M., Owicki, J.C., Parce, J.W., Miller, D.L., Baxter, G.T., Wadw, H.G., Pitchford, S., 1992. The Cytosensor Microphysiometer: biological application of silicon technology. Science 257, 1906–1912.
- Orlowski, J., Grinstein, S., 1997. Na<sup>+</sup>/H<sup>+</sup> exchangers of mammalian cells. J. Biol. Chem. 272, 22373–22376.

- Peltonen, J.M., Pihlavisto, M., Scheinin, M., 1998. Subtype-specific stimulation of [ $^{35}$ S]GTP $\gamma$ S binding by recombinant  $\alpha_2$ -adrenoceptors. Eur. J. Pharmacol. 355, 275–279.
- Pohjanoksa, K., Jansson, C.C., Luomala, K., Marjamäki, A., Savola, J.-M., Scheinin, M., 1997.  $\alpha_2$ -Adrenoceptor regulation of adenylyl cyclase in CHO cells: dependence on receptor density, receptor subtype and current activity of adenylyl cyclase. Eur. J. Pharmacol. 335, 53–63.
- Shimegi, S., Okajima, F., Kondo, Y., 1994. Permissive stimulation of  ${\rm Ca^{2^+}}$ -induced phospholipase  ${\rm A_2}$  by an adenosine receptor agonist in a pertussis toxin-sensitive manner in FRTL-5 thyroid cells: a new 'cross-talk': mechanism in  ${\rm Ca^{2^+}}$  signalling. Biochem. J. 299, 845–851.
- Smith, A.J., McKernan, R.M., Atack, J.R., 1998. Benzodiazepine modulation of recombinant α1β3γ2GABA(A) receptor function efficacy

- determination using the Cytosensor microphysiometer. Eur. J. Pharmacol. 359, 261–269.
- Soini, S.L., Duzic, E., Lanier, S.M., Åkerman, K.E.O., 1998. Dual modulation of calcium channel current via recombinant  $\alpha_2$ -adrenoceptors in pheochromocytoma (PC-12) cells. Pflüger's Arch.-Eur. J. Physiol. 435, 280–285.
- Virolainen, S., Jansson, C.C., Scheinin, M., 1997. Assessment of  $\alpha_2$ -adrenoceptor antagonist potency with GTPase assay. Eur. J. Pharmacol. 338, 293–296.
- Wood, M.D., Murkitt, K.L., Ho, M., Watson, J.M., Brown, F., Hunter, A.J., Middlemiss, D.N., 1999. Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM<sub>1</sub>, hM<sub>2</sub>, hM<sub>3</sub>, hM<sub>4</sub> and hM<sub>5</sub> using microphysiometry. Br. J. Pharmacol. 126, 1620– 1624.